Comparing Intec Pharma (NTEC) & Its Competitors

Intec Pharma (NASDAQ: NTEC) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Intec Pharma to similar companies based on the strength of its valuation, earnings, analyst recommendations, risk, profitability, institutional ownership and dividends.


This table compares Intec Pharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intec Pharma N/A N/A N/A
Intec Pharma Competitors -5,310.77% -218.27% -39.48%

Analyst Ratings

This is a summary of recent ratings for Intec Pharma and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intec Pharma 0 0 4 0 3.00
Intec Pharma Competitors 882 3256 11745 235 2.70

Intec Pharma presently has a consensus target price of $12.00, indicating a potential upside of 129.67%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.63%. Given Intec Pharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe Intec Pharma is more favorable than its peers.

Valuation and Earnings

This table compares Intec Pharma and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intec Pharma N/A -$13.36 million N/A
Intec Pharma Competitors $284.49 million $34.10 million 77.05

Intec Pharma’s peers have higher revenue and earnings than Intec Pharma.

Institutional & Insider Ownership

40.2% of Intec Pharma shares are held by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Intec Pharma has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Intec Pharma’s peers have a beta of 6.25, meaning that their average share price is 525% more volatile than the S&P 500.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit